electroCore(US:ECOR)2026-03-19 21:32Financial Data and Key Metrics Changes - Revenue for Q4 2025 reached a record $9.2 million, up 31% year-over-year, bringing full year 2025 revenue to $32 million, a 27% increase over 2024 [14][18] - Prescription device revenue increased 23% year-over-year to $26 million, driven by growth in gammaCore and Quell products [14][18] - Net loss for 2025 was $14 million or $1.65 per share, compared to a net loss of $11.9 million or $1.59 per share in 2024 [21][22] Business Line Data and Key Metrics Changes - VA hospital system remains the largest customer, with 200 facilities purchasing gammaCore products, up from 170 a year ago [14][15] - General wellness revenue reached $5.5 million for the full year, a 97% increase compared to 2024, primarily driven by Truvaga sales [15][16] - Truvaga sales increased by 93% from 2024, totaling $5.4 million [16] Market Data and Key Metrics Changes - Approximately 13,400 VA patients received gammaCore devices, representing roughly 2% penetration of the addressable VA headache market [15] - NHS England remains a key channel for international sales, with ongoing efforts to develop infrastructure for reimbursement in other countries [38] Company Strategy and Development Direction - The company is focused on increasing sales within the VA system and expanding into general wellness with the Truvaga product [8][12] - A leadership transition is underway, with Joshua Lev appointed as Interim President and Michael Fox joining as Chief Operating Officer to enhance commercial efforts [5][8] - The company aims to introduce additional wellness offerings and a next-generation mobile application to support recurring revenue opportunities [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained revenue acceleration and long-term value creation [12][23] - The leadership transition is seen as an opportunity to maintain operational momentum while focusing on growth strategies [6][7] - The company expects 2026 revenue to continue growing at approximately 30% [23] Other Important Information - Gross margin improved to 87% compared to 85% in 2024 [18] - Research and development expenses increased to $2.7 million, primarily for gammaCore Emerald and mobile application development [19] Q&A Session Summary Question: Can you discuss the channels for gammaCore and Quell in 2026? - Management highlighted the growth in the VA channel and the addition of commercial leaders to accelerate growth [30][31] Question: What about the OUS channels and specific geographies? - NHS England remains the primary focus for international revenue, with ongoing efforts to develop reimbursement pathways in other countries [35][38] Question: Will Michael Fox focus on the VA business while Joshua handles wellness? - Michael will oversee broader commercial strategies, including VA and other federal systems, while Joshua will manage wellness products [44][45] Question: Any updates on insurance reimbursement coverage? - The company is focused on Kaiser as a key opportunity for broader reimbursement adoption, with plans to leverage success for additional managed care systems [58][59]